Lixte Biotechnology (LIXT) Competitors $1.31 +0.08 (+6.50%) As of 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIXT vs. PHIO, ME, AYTU, LIPO, ATHA, NEUP, NERV, AIMD, BCTX, and ALLRShould you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Phio Pharmaceuticals (PHIO), 23andMe (ME), Aytu BioPharma (AYTU), Lipella Pharmaceuticals (LIPO), Athira Pharma (ATHA), Neuphoria Therapeutics Inc. - Common Stock (NEUP), Minerva Neurosciences (NERV), Ainos (AIMD), BriaCell Therapeutics (BCTX), and Allarity Therapeutics (ALLR). These companies are all part of the "pharmaceutical products" industry. Lixte Biotechnology vs. Its Competitors Phio Pharmaceuticals 23andMe Aytu BioPharma Lipella Pharmaceuticals Athira Pharma Neuphoria Therapeutics Inc. - Common Stock Minerva Neurosciences Ainos BriaCell Therapeutics Allarity Therapeutics Phio Pharmaceuticals (NASDAQ:PHIO) and Lixte Biotechnology (NASDAQ:LIXT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations. Does the media favor PHIO or LIXT? In the previous week, Phio Pharmaceuticals had 12 more articles in the media than Lixte Biotechnology. MarketBeat recorded 14 mentions for Phio Pharmaceuticals and 2 mentions for Lixte Biotechnology. Lixte Biotechnology's average media sentiment score of 1.44 beat Phio Pharmaceuticals' score of 0.93 indicating that Lixte Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Phio Pharmaceuticals Positive Lixte Biotechnology Positive Which has more risk and volatility, PHIO or LIXT? Phio Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Lixte Biotechnology has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500. Do analysts prefer PHIO or LIXT? Phio Pharmaceuticals presently has a consensus target price of $14.00, suggesting a potential upside of 466.80%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Phio Pharmaceuticals is more favorable than Lixte Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lixte Biotechnology 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in PHIO or LIXT? Phio Pharmaceuticals received 39 more outperform votes than Lixte Biotechnology when rated by MarketBeat users. CompanyUnderperformOutperformPhio PharmaceuticalsOutperform Votes3965.00% Underperform Votes2135.00% Lixte BiotechnologyN/AN/A Is PHIO or LIXT more profitable? Phio Pharmaceuticals' return on equity of -134.57% beat Lixte Biotechnology's return on equity.Company Net Margins Return on Equity Return on Assets Phio PharmaceuticalsN/A -134.57% -108.39% Lixte Biotechnology N/A -5,562.77%-130.48% Which has stronger valuation and earnings, PHIO or LIXT? Lixte Biotechnology is trading at a lower price-to-earnings ratio than Phio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhio PharmaceuticalsN/AN/A-$10.83M-$10.92-0.23Lixte BiotechnologyN/AN/A-$5.09M-$1.45-0.90 Do insiders and institutionals hold more shares of PHIO or LIXT? 57.3% of Phio Pharmaceuticals shares are held by institutional investors. Comparatively, 5.1% of Lixte Biotechnology shares are held by institutional investors. 0.6% of Phio Pharmaceuticals shares are held by insiders. Comparatively, 14.8% of Lixte Biotechnology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryPhio Pharmaceuticals beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks. Get Lixte Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for LIXT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIXT vs. The Competition Export to ExcelMetricLixte BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.52M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.768.6727.1419.96Price / SalesN/A262.53411.83157.63Price / CashN/A65.8538.2534.64Price / Book5.956.597.064.69Net Income-$5.09M$143.75M$3.23B$248.14M7 Day Performance-5.08%3.72%2.67%2.39%1 Month Performance2.34%11.01%8.82%6.05%1 Year Performance-49.23%3.87%31.44%13.60% Lixte Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIXTLixte Biotechnology1.0597 of 5 stars$1.31+6.5%N/A-49.2%$3.52MN/A-0.764Positive NewsShort Interest ↓Gap UpPHIOPhio Pharmaceuticals3.7813 of 5 stars$2.79-5.7%$14.00+401.8%-62.2%$13.39MN/A-0.2610Short Interest ↓Analyst RevisionGap UpME23andMeN/A$0.50-35.3%N/A-94.0%$13.36M$208.78M-0.03770Gap DownHigh Trading VolumeAYTUAytu BioPharma1.4903 of 5 stars$2.11+5.5%N/A-36.4%$13.02M$81.66M-1.46160Short Interest ↓Gap UpHigh Trading VolumeLIPOLipella Pharmaceuticals2.3339 of 5 stars$2.91-2.7%N/A-46.4%$13.00M$536.36K-0.684ATHAAthira Pharma2.8772 of 5 stars$0.33-8.1%$13.83+4,079.3%-87.4%$12.92MN/A-0.1240NEUPNeuphoria Therapeutics Inc. - Common Stock2.0286 of 5 stars$6.82-0.7%$21.00+207.9%N/A$12.92M$15.66M0.00N/ANERVMinerva Neurosciences3.4286 of 5 stars$1.84flat$5.00+171.7%-44.6%$12.87MN/A-4.189News CoveragePositive NewsAIMDAinos1.3923 of 5 stars$0.62-6.2%N/A-35.3%$12.84M$106.21K-0.4840Gap DownBCTXBriaCell Therapeutics1.7201 of 5 stars$3.48+1.2%$32.00+819.5%-82.4%$12.76MN/A-0.268News CoverageUpcoming EarningsShort Interest ↑ALLRAllarity Therapeutics0.549 of 5 stars$0.88+4.2%N/A-94.0%$12.76MN/A0.0010News Coverage Related Companies and Tools Related Companies PHIO Alternatives ME Alternatives AYTU Alternatives LIPO Alternatives ATHA Alternatives NEUP Alternatives NERV Alternatives AIMD Alternatives BCTX Alternatives ALLR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIXT) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lixte Biotechnology Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lixte Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LIXT Stock Free LIXT Stock Alerts